NeuroPace (NASDAQ:NPCE) and IDEXX Laboratories (NASDAQ:IDXX) Head-To-Head Contrast

IDEXX Laboratories (NASDAQ:IDXX) and NeuroPace (NASDAQ:NPCE) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, earnings, profitability, valuation and risk.

Valuation and Earnings

This table compares IDEXX Laboratories and NeuroPace”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IDEXX Laboratories	$4.30 billion	10.09	$1.06 billion	$14.22	38.76
NeuroPace	$99.99 million	4.22	-$21.47 million	($0.57)	-21.58

IDEXX Laboratories has higher revenue and earnings than NeuroPace. NeuroPace is trading at a lower price-to-earnings ratio than IDEXX Laboratories, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current ratings and price targets for IDEXX Laboratories and NeuroPace, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IDEXX Laboratories	0	6	8	0	2.57
NeuroPace	1	1	7	1	2.80

IDEXX Laboratories presently has a consensus target price of $721.67, indicating a potential upside of 30.92%. NeuroPace has a consensus target price of $19.33, indicating a potential upside of 57.18%. Given NeuroPace’s stronger consensus rating and higher probable upside, analysts clearly believe NeuroPace is more favorable than IDEXX Laboratories.

Risk and Volatility

IDEXX Laboratories has a beta of 1.55, suggesting that its share price is 55% more volatile than the S&P 500. Comparatively, NeuroPace has a beta of 1.86, suggesting that its share price is 86% more volatile than the S&P 500.

Profitability

This table compares IDEXX Laboratories and NeuroPace’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
IDEXX Laboratories	25.03%	71.96%	33.60%
NeuroPace	-19.34%	-105.64%	-16.51%

Insider and Institutional Ownership

87.8% of IDEXX Laboratories shares are owned by institutional investors. Comparatively, 78.8% of NeuroPace shares are owned by institutional investors. 0.8% of IDEXX Laboratories shares are owned by company insiders. Comparatively, 19.2% of NeuroPace shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

IDEXX Laboratories beats NeuroPace on 10 of the 15 factors compared between the two stocks.

About IDEXX Laboratories

IDEXX Laboratories, Inc. develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy. It also provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and health monitoring, biological materials testing, and laboratory diagnostic instruments, and services for biomedical research community. In addition, the company offers diagnostic and health-monitoring products for livestock, poultry, and dairy; products that test water for various microbiological contaminants; point-of-care electrolytes and blood gas analyzers; in-clinic chemistry, blood and urine chemistry, hematology, immunoassay, urinalysis, and coagulation analyzers; and SNAP rapid assays test kits. Further, it provides Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, and Quanti-Tray products; and veterinary software and services for independent veterinary clinics and corporate groups. Additionally, the company offers human medical point-of-care products and laboratory diagnostics services. The company markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.

About NeuroPace

NeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely. Its RNS System includes RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories. The company sells its products to hospital facilities for initial RNS system implant procedures and for replacement procedures. NeuroPace, Inc. was incorporated in 1997 and is headquartered in Mountain View, California.